目的: 探究选择性环氧合酶-2(COX-2)抑制剂是否加重佐剂性关节炎大鼠胃黏膜损伤及其机制。方法: 将32只雄性SD大鼠随机分为空白对照组、关节炎对照组、正常给药组和关节炎给药组,给予选择性COX-2抑制剂塞来昔布灌胃4周,取大鼠胃组织行HE染色损伤评分以及大体损伤评分。结果: 关节炎对照组、关节炎给药组大鼠胃黏膜损伤病理评分以及大体评分与空白对照组相比均增加;正常给药组大鼠胃黏膜损伤病理评分以及大体评分与空白对照组相比均无显著差异;关节炎用药组大鼠胃黏膜损伤病理评分以及大体评分与关节炎对照组相比均无显著差异。结论: 在治疗剂量下,塞来昔布不会造成正常大鼠胃黏膜损伤,也不会加重佐剂性关节炎大鼠胃黏膜的损伤;佐剂性关节炎大鼠存在胃黏膜损伤,这可能与关节炎所致全身慢性炎症有关。
Objective: To investigate whether selective COX-2 inhibitors aggravate gastric mucosal injury and its mechanism in adjuvant induced arthritis rats. Methods: 32 male SD rats were randomly divided into blank control group, arthritis control group, normal administration group and arthritis administration group. They were given celecoxib, a selective COX-2 inhibitor, by gavage for 4 weeks. Then take the gastric tissue of rats for HE staining injury score and gross injury score. Results: The pathological score and gross score of gastric mucosal injury in arthritis control group and arthritis administration group were higher than those in blank control group; There was no significant difference in the pathological score and gross score of gastric mucosal injury between the normal administration group and the blank control group; There was no significant difference in the pathological score and gross score of gastric mucosal injury between the arthritis administration group and the arthritis control group. Conclusion: At the therapeutic dose, celecoxib, a selective COX-2 inhibitor, did not cause gastric mucosal damage in normal rats or aggravate gastric mucosal damage in adjuvant arthritis rats. There was gastric mucosal injury in adjuvant arthritis rats. Gastric mucosal injury in adjuvant arthritis rats may be related to the systemic chronic inflammation caused by arthritis.
[1] Tai FWD, Mcalindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract[J]. Clin Med (Lond), 2021,21(2):131-134.
[2] Kato S, Ogawa Y, Kanatsu K, et al. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis[J]. J Pharmacol Exp Ther, 2002,303(2):503-509.
[3] Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial[J]. Aliment Pharmacol Ther, 2018,47(11):1453-1463.
[4] Choudhary N, Bhatt LK, Prabhavalkar KS. Experimental animal models for rheumatoid arthritis[J]. Immunopharmacol Immunotoxicol, 2018,40(3):193-200.
[5] Etani R, Kataoka T, Kanzaki N, et al. Protective effects of hot spring water drinking and radon inhalation on ethanol-induced gastric mucosal injury in mice[J]. J Radiat Res, 2017,58(5):614-625.
[6] Guth PH, Aures D, Paulsen G. Topical aspirin plus HCl gastric lesions in the rat. Cytoprotective effect of prostaglandin, cimetidine, and probanthine[J]. Gastroenterology, 1979,76(1):88-93.
[7] Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[J]. JAMA, 2000,284(10):1247-1255.
[8] Sparks JA. Rheumatoid arthritis[J]. Ann Intern Med, 2019,170(1):ITC1-ITC16.
[9] 刘健,夏伦祝,冯艺戎,等. 以Annexin V/PI法检测新风胶囊对AA大鼠滑膜、胸腺及胃黏膜细胞凋亡的影响[J]. 安徽医药,2004,8(1):14-16.
[10] Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs[J]. Gastroenterology, 2018,154(3):500-514.
[11] Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract[J]. Adv Clin Chem, 2010,51:121-144.
[12] Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis[J]. J Rheumatol, 2000,27(10):2339-2342.
[13] Tarnawski AS, Ahluwalia A. The critical role of growth factors in gastric ulcer healing: the cellular and molecular mechanisms and potential clinical implications[J]. Cells, 2021,10(8):1964.
[14] Blackler R, Syer S, Bolla M, et al. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence[J]. PLoS One, 2012,7(4):e35196.
[15] Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view[J]. Clin Cardiol,2017,40(12):1352-1356.
